ASP9521
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate Resistant Prostate Cancer
Conditions
Castrate Resistant Prostate Cancer
Trial Timeline
Mar 1, 2011 → Sep 1, 2012
NCT ID
NCT01352208About ASP9521
ASP9521 is a phase 1/2 stage product being developed by Astellas Pharma for Castrate Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01352208. Target conditions include Castrate Resistant Prostate Cancer.
What happened to similar drugs?
1 of 4 similar drugs in Castrate Resistant Prostate Cancer were approved
Approved (1) Terminated (1) Active (2)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01352208 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Castrate Resistant Prostate Cancer